Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications

Kedika, Ramalinga R.; Souza, Rhonda F.; Spechler, Stuart Jon
November 2009
Digestive Diseases & Sciences;Nov2009, Vol. 54 Issue 11, p2312
Academic Journal
journal article
Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, and are widely regarded as the agents of choice for the treatment of acid-peptic disorders. For patients with upper gastrointestinal symptoms of uncertain etiology, improvement with PPI therapy is considered prima facie evidence of a pathogenetic role for acid-peptic disease. In addition to anti-secretory effects, however, PPIs have been found to have anti-oxidant properties and direct effects on neutrophils, monocytes, endothelial, and epithelial cells that might prevent inflammation. Those anti-inflammatory effects of the PPIs might influence a variety of inflammatory disorders, both peptic and non-peptic, within and outside of the gastrointestinal tract. The purpose of this report is to review the mechanisms whereby PPIs might exert anti-inflammatory effects exclusive of gastric acid inhibition, to discuss the clinical implications of those effects, and to emphasize that a clinical response to PPIs should not be construed as proof for an underlying acid-peptic disorder.


Related Articles

  • Proton Pump Inhibitors Decrease Eotaxin-3 Expression in the Proximal Esophagus of Children with Esophageal Eosinophilia. Park, Jason Y.; Zhang, Xi; Nguyen, Nathalie; Souza, Rhonda F.; Spechler, Stuart J.; Cheng, Edaire // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Objective: Besides reducing gastric acid secretion, proton pump inhibitors (PPIs) suppress Th2-cytokine-stimulated expression of an eosinophil chemoattractant (eotaxin-3) by esophageal epithelial cells through acid-independent, anti-inflammatory mechanisms. To explore acid-inhibitory and...

  • Rabeprazole: quest for the best PPI. Sugano, Kentaro // Journal of Gastroenterology;2002, Vol. 37 Issue 3, p233 

    Editorial. Comments on an article dealing with the effects of proton pump inhibitors (PPI) rabeprazole and omeprazole on parietal cells and other acid regulatory cells in the rat stomach. Details on the study; Background on PPI; Recommendations.

  • Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children. Scott, L.J. // Pediatric Drugs;2003, Vol. 5 Issue 1, p57 

    â–´ Lansoprazole, a proton pump inhibitor, inactivates the H/K-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. â–´ After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at...

  • The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. Salim Bastaki; Irwin Chandranath; Jaipaul Singh // Molecular & Cellular Biochemistry;Feb2008, Vol. 309 Issue 1/2, p167 

    Abstract   Proton pump inhibitors (PPIs) are widely used to treat hyperacid secretion and stomach ulcers. The study investigated the anti-secretory and anti-ulcer effects of esomeprazole, the S-isomer of omeprazole on dimaprit, histamine and dibutyryl adenosine 3, 5 cyclic...

  • Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers. Wilder-Smith, Clive; Jansson, Lennart; Röhss, Kerstin; Nauclér, Emma // Clinical Drug Investigation;2004, Vol. 24 Issue 1, p1 

    Objective: A high proportion of patients with gastro-oesophageal reflux disease experience recurrence of symptoms within a year of initial treatment. The key to preventing relapse is an effective maintenance therapy that maintains intragastric pH >4. This study was conducted to compare the...

  • PPIs, Clostridium difficile, and Bone Fractures. Elliott, William T. // Critical Care Alert;Jul2010 Pharmacology, p1 

    The article presents a study on proton pump inhibitors (PPls) and the impact of gastric acid suppression on Clostridium difficile infection (CDI) which shows that PPl use is associated with risk of osteoporotic fractures and CDI.

  • Pantoprazole Therapy in the Long-Term Management of Severe Acid Peptic Disease. Bardhan, Karna Dev; Cherian, Pradip; Bishop, Anne E.; Polak, Julia M.; Perry, Michael J.; Rowland, Anne; Thompson, Mary; Morris, Pamela; Schneider, Andreas; Fischer, Renata; Ng, W.; Lühmann, R.; McCaldin, Brian // American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1767 

    OBJECTIVE: Pantoprazole is the third proton pump inhibitor to become available. When this study was started, there were few data on its long-term use. Our aim was to investigate this aspect and, because powerful inhibitors of acid secretion can cause hypergastrinemia and, in experimental...

  • Proton Pump Inhibitors: Do Differences in Pharmacokinetics Translate into Differences in Clinical Outcomes? Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Jon Deon Lee, Edmund // Clinical Pharmacokinetics;2008, Vol. 47 Issue 1, p1 

    Acid-related disorders are common management problems in clinical practice. The key to effective management is successful suppression of gastric acid production. Proton pump inhibitors (PPIs) are the most potent acid suppressants available and are significantly more effective than histamine H2...

  • Aspects of the Theoretical Basis and Clinical Relevance of Low Acid States. Modlin, Irvin M.; Goldenring, James R.; Lawton, Gary P.; Hunt, Richard // American Journal of Gastroenterology;Mar1994, Vol. 89 Issue 3, p308 

    Examines the theoretical basis and clinical relevance of both the short- and long-term results of profound suppression of gastric acid secretion. General concerns regarding the long-term maintenance of a low acid state; Characterization of low acid states; Complications associated with low acid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics